First Do No Harm: US MedPAC Wrestles With Complexity Of Low-Cost Drug Pricing
Executive Summary
The US Medicare Payment Advisory Commission is analyzing two of the lower-cost segments of the US medicine marketplace: generic drugs and the 340B brand discount program. In both cases, there is a picture of complexity and unintended consequences to rival higher cost segments.